Timely HAART initiation may pave the way for a better viral control.

ABSTRACT:

Background

When to initiate antiretroviral therapy in HIV infected patients is a difficult clinical decision. Actually, it is still a matter of discussion whether early highly active antiretroviral therapy (HAART) during primary HIV infection may influence the dynamics of the viral rebound, in case of therapy interruption, and overall the main disease course.

Methods

In this article we use a computational model and clinical data to identify the role of HAART timing on the residual capability to control HIV rebound after treatment suspension. Analyses of clinical data from three groups of patients initiating HAART respectively before seroconversion (very early), during the acute phase (early) and in the chronic phase (late), evidence differences arising from the very early ev

SUBMITTER: Paci P 

PROVIDER: S-EPMC3058048 | biostudies-literature | 2011 Mar

REPOSITORIES: biostudies-literature